Evolent Health, Inc. (EVH) Presents at UBS Global Healthcare Conference 2025 Transcript

Evolent Health, Inc. ( EVH ) UBS Global Healthcare Conference 2025 November 11, 2025 5:00 PM EST Company Participants John Johnson - Chief Financial Officer Conference Call Participants Kevin Caliendo - UBS Investment Bank, Research Division Presentation Kevin Caliendo UBS Investment Bank, Research Division Good afternoon. This is Kevin Caliendo, health care service and distribution and IT analyst from UBS.

Seeking Alpha • Nov 12, 2025

Evolent Health, Inc. (EVH) Q3 2025 Earnings Call Transcript

Evolent Health, Inc. ( EVH ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Seth Blackley - Co-Founder, CEO & Director John Johnson - Chief Financial Officer Conference Call Participants Kevin Caliendo - UBS Investment Bank, Research Division Daniel Grosslight - Citigroup Inc., Research Division John Stansel - JPMorgan Chase & Co, Research Division Lucas Romanski - TD Cowen, Research Division Eduardo Ron - Truist Securities, Inc., Research Division Jeffrey Garro - Stephens Inc., Research Division Jessica Tassan - Piper Sandler & Co., Research Division David Larsen - BTIG, LLC, Research Division Matthew Shea - Needham & Company, LLC, Research Division Matthew Gillmor - KeyBanc Capital Markets Inc., Research Division Presentation Operator Welcome to the Evolent Earnings Conference Call for the Third Quarter ended September 30, 2025. As a reminder, this conference call is being recorded.

Seeking Alpha • Nov 7, 2025

Evolent Announces Third Quarter 2025 Results

Q3 2025 financial results ahead of expectations. Announces more than $500 million in newly-contracted annualized revenue to launch in 2026.

PRNewsWire • Nov 6, 2025

Evolent Health (EVH) Misses Q3 Earnings Estimates

Evolent Health (EVH) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.04 per share a year ago.

Zacks Investment Research • Nov 7, 2025

Compared to Estimates, Evolent Health (EVH) Q3 Earnings: A Look at Key Metrics

The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Nov 7, 2025

Evolent and American Oncology Network unveil innovative model seeking to improve cancer care while eliminating prior authorization burden

WASHINGTON , Nov. 6, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, and American Oncology Network (AON), one of the nation's fastest-growing community oncology networks, today announced a new model enabling high-quality, more affordable, and connected cancer care — all without relying on prior authorization. The national partnership seeks to improve clinical decision-making by introducing quality-focused interventions, driving clinical insights through an innovative data and analytics platform, and rewarding providers for high-quality care.

PRNewsWire • Nov 6, 2025

Evolent To Release Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Company to Participate in Upcoming Conferences WASHINGTON , Oct. 9, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its third quarter 2025 financial results on Thursday, November 6, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.

PRNewsWire • Oct 9, 2025

Evolent Announces Strategic Divestiture of its Value-Based Primary Care Business, Evolent Care Partners

Transaction enhances focus on specialty condition management and accelerates Evolent's deleveraging path. Proceeds from the transaction to be used to prepay senior term debt; Immediately accretive to Evolent's free cash flow by more than $7 million per year.

PRNewsWire • Sep 23, 2025

CVS vs. EVH: Which Value-Based Care Stock Deserves Investor Attention?

CVS shows revenue growth and raised guidance, while EVH faces revenue declines but pursues oncology deals and efficiency gains.

Zacks Investment Research • Sep 17, 2025

Evolent's Soft Q2 Results: Why I'm Holding Anyway

Evolent's revenue dip in Q1 was structural, not demand-driven, and Q2 shows stabilization; I expect growth to resume in the second half of 2025. New specialty contracts, incremental member growth, and key leadership appointments should drive recovery and enhance clinical and financial credibility. The oversubscribed convertible notes offering signals investor confidence, strengthens liquidity, and supports shareholder value through buybacks and reduced refinancing risk.

Seeking Alpha • Aug 21, 2025